Drugs / XXB750
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05328752 | May 2022 → Jan 2024 | systolic heart failure | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT06558097 | Jul 2020 → Mar 2023 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 22 trials · 2 missed | ||||||
| Phase 2 | NCT06142383 | Dec 2023 → Nov 2024 | heart failure | Novartis Pharmaceuticals | Terminated | Missed primary Stop: Business |
| Phase 2 | NCT05562934 | Nov 2022 → Jul 2024 | resistant hypertension | Novartis Pharmaceuticals | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XXB750 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05562934 ↗ |
| Action | Activate | “XXB750, an NPR-1 agonist, had a neutral effect on 24-hour ambulatory SBP” PMID 41563174 ↗ Jan 2026 |
| Modality | Monoclonal antibody | “XXB750 is a potent and long-acting human monoclonal antibody agonist” PMID 41563174 ↗ Jan 2026 |
| Route | Subcutaneous | “receive a single dose of subcutaneous (s.c) XXB750 or placebo.” NCT05328752 ↗ |
| Target | NPR1 | “XXB750, a human monoclonal antibody activating natriuretic peptide receptor 1” PMID 41912806 ↗ Mar 2026 |